Literature DB >> 33031233

Maximum Uptake and Hypermetabolic Volume of 18F-FDOPA PET Estimate Molecular Status and Overall Survival in Low-Grade Gliomas: A PET and MRI Study.

Hiroyuki Tatekawa, Jingwen Yao, Talia C Oughourlian, Akifumi Hagiwara, Chencai Wang, Catalina Raymond, Albert Lai, Timothy F Cloughesy, Phioanh L Nghiemphu, Linda M Liau, Noriko Salamon1, Benjamin M Ellingson.   

Abstract

PURPOSE: We evaluated F-FDOPA PET and MRI characteristics in association with the molecular status and overall survival (OS) in a large number of low-grade gliomas (LGGs).
METHODS: Eighty-six patients who underwent F-FDOPA PET and MRI and were diagnosed with new or recurrent LGGs were retrospectively evaluated with respect to their isocitrate dehydrogenase (IDH) and 1p19q status (10 IDH wild type, 57 mutant, 19 unknown; 1p19q status in IDH mutant: 20 noncodeleted, 37 codeleted). After segmentation of the hyperintense area on fluid-attenuated inversion recovery image (FLAIRROI), the following were calculated: normalized SUVmax (nSUVmax) of F-FDOPA relative to the striatum, F-FDOPA hypermetabolic volume (tumor-to-striatum ratios >1), FLAIRROI volume, relative cerebral blood volume, and apparent diffusion coefficient within FLAIRROI. Receiver operating characteristic curve and Cox regression analyses were performed.
RESULTS: PET and MRI metrics combined with age predicted the IDH mutation and 1p19q codeletion statuses with sensitivities of 73% and 76% and specificities of 100% and 94%, respectively. Significant correlations were found between OS and the IDH mutation status (hazard ratio [HR] = 4.939), nSUVmax (HR = 2.827), F-FDOPA hypermetabolic volume (HR = 1.048), and FLAIRROI volume (HR = 1.006). The nSUVmax (HR = 151.6) for newly diagnosed LGGs and the F-FDOPA hypermetabolic volume (HR = 1.038) for recurrent LGGs demonstrated significant association with OS.
CONCLUSIONS: Combining F-FDOPA PET and MRI with age proved useful for predicting the molecular status in patients with LGGs, whereas the nSUVmax and F-FDOPA hypermetabolic volume may be useful for prognostication.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33031233      PMCID: PMC7950323          DOI: 10.1097/RLU.0000000000003318

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   10.782


  31 in total

Review 1.  Radiolabeled amino acids for oncologic imaging.

Authors:  Chaofeng Huang; Jonathan McConathy
Journal:  J Nucl Med       Date:  2013-05-24       Impact factor: 10.057

2.  Prognostic Value of O-(2-[18F]Fluoroethyl)-L-Tyrosine PET/CT in Newly Diagnosed WHO 2016 Grade II and III Glioma.

Authors:  Olivia Kertels; Almuth F Kessler; Milena I Mihovilovic; Antje Stolzenburg; Thomas Linsenmann; Samuel Samnick; Stephanie Brändlein; Camelia Maria Monoranu; Ralf-Ingo Ernestus; Andreas K Buck; Mario Löhr; Constantin Lapa
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

3.  18F-DOPA uptake parameters in glioma: effects of patients' characteristics and prior treatment history.

Authors:  Luciano Carideo; Giuseppe Minniti; Marcelo Mamede; Claudia Scaringi; Ivana Russo; Francesco Scopinaro; Francesco Cicone
Journal:  Br J Radiol       Date:  2018-01-19       Impact factor: 3.039

4.  Prognostic value of volume-based measurements on (11)C-methionine PET in glioma patients.

Authors:  Kentaro Kobayashi; Kenji Hirata; Shigeru Yamaguchi; Osamu Manabe; Shunsuke Terasaka; Hiroyuki Kobayashi; Tohru Shiga; Naoya Hattori; Shinya Tanaka; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-08       Impact factor: 9.236

5.  Proton irradiation of [18O]O2: production of [18F]F2 and [18F]F2 + [18F] OF2.

Authors:  A Bishop; N Satyamurthy; G Bida; G Hendry; M Phelps; J R Barrio
Journal:  Nucl Med Biol       Date:  1996-04       Impact factor: 2.408

6.  Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patients.

Authors:  Norbert Galldiks; Marcus Unterrainer; Natalie Judov; Gabriele Stoffels; Marion Rapp; Philipp Lohmann; Franziska Vettermann; Veronika Dunkl; Bogdana Suchorska; Jörg C Tonn; Friedrich-Wilhem Kreth; Gereon R Fink; Peter Bartenstein; Karl-Josef Langen; Nathalie L Albert
Journal:  Neuro Oncol       Date:  2019-10-09       Impact factor: 12.300

7.  Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.

Authors:  Barbara J Fueger; Johannes Czernin; Timothy Cloughesy; Daniel H Silverman; Cheri L Geist; Martin A Walter; Christiaan Schiepers; Phioanh Nghiemphu; Albert Lai; Michael E Phelps; Wei Chen
Journal:  J Nucl Med       Date:  2010-09-16       Impact factor: 10.057

8.  Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM.

Authors:  Bogdana Suchorska; Nathalie L Jansen; Jennifer Linn; Hans Kretzschmar; Hendrik Janssen; Sabina Eigenbrod; Matthias Simon; Gabriele Pöpperl; Friedrich W Kreth; Christian la Fougere; Michael Weller; Joerg C Tonn
Journal:  Neurology       Date:  2015-01-21       Impact factor: 9.910

9.  Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.

Authors:  Benjamin M Ellingson; Hyun J Kim; Davis C Woodworth; Whitney B Pope; Jonathan N Cloughesy; Robert J Harris; Albert Lai; Phioanh L Nghiemphu; Timothy F Cloughesy
Journal:  Radiology       Date:  2013-11-27       Impact factor: 11.105

10.  Amino acid tracers in PET imaging of diffuse low-grade gliomas: a systematic review of preoperative applications.

Authors:  Olivia Näslund; Anja Smits; Petter Förander; Mats Laesser; Jiri Bartek; Jens Gempt; Ann Liljegren; Eva-Lotte Daxberg; Asgeir Store Jakola
Journal:  Acta Neurochir (Wien)       Date:  2018-05-24       Impact factor: 2.216

View more
  1 in total

1.  Maximum 11C-methionine PET uptake as a prognostic imaging biomarker for newly diagnosed and untreated astrocytic glioma.

Authors:  Kosuke Nakajo; Takehiro Uda; Toshiyuki Kawashima; Yuzo Terakawa; Kenichi Ishibashi; Naohiro Tsuyuguchi; Yuta Tanoue; Atsufumi Nagahama; Hiroshi Uda; Saya Koh; Tsuyoshi Sasaki; Kenji Ohata; Yonehiro Kanemura; Takeo Goto
Journal:  Sci Rep       Date:  2022-01-11       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.